Author contributions: R.J. and D.M.: designed the study, performed research, analyzed data, wrote the manuscript; L.V.B.: collected material, provided clinical information; S.V. and G.M.: helped analyzing data; O.R. designed the clinical study, helped writing the manuscript; R.K.: helped designing the experiments; S.L.: performed research; K.L.B.: designed the study, analyzed data, wrote the manuscript. R.J. and D.M. contributed equally to this study.
Translational and Clinical Research
Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation†
Article first published online: 23 AUG 2013
Copyright © 2013 AlphaMed Press
Volume 31, Issue 8, pages 1715–1725, August 2013
How to Cite
Jitschin, R., Mougiakakos, D., Von Bahr, L., Völkl, S., Moll, G., Ringden, O., Kiessling, R., Linder, S. and Le Blanc, K. (2013), Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation. STEM CELLS, 31: 1715–1725. doi: 10.1002/stem.1386
- Issue published online: 23 AUG 2013
- Article first published online: 23 AUG 2013
- Accepted manuscript online: 4 APR 2013 01:12AM EST
- Manuscript Accepted: 7 MAR 2013
- Manuscript Received: 16 DEC 2012
Additional Supporting Information may be found in the online version of this article.
|STEM_1386_sm_SuppFig.tiff||1720K||Supplemental Figure Legends: (A) Frequency of CD3+ CD4 and CD8 double negative (DN) T-cells in MSC treated (green) and placebo (red) treated patients at day +30, +90 and +180 post infusion as well as 10 healthy donors. Horizontal line depicts arithmetic mean and the grey area range of values (5th- 95th percentile) of the healthy donors. (B) The fraction of CD62L+ regulatory T-cells (Treg) was evaluated in both groups as well as in healthy donors (n=10) (HD/blue). (C and D) In both myeloid DCs (mDCs) (panel C) and plasmacytoid DCs (pDCs) (panel D), the expression density of the maturation marker CD83 and the co-stimulatory molecule CD86 was studied. (E) The frequency of CD14+ monocytes was evaluated as shown in the representative FACS analysis. (F) Level of HLA-DR surface density in CD14+ monocytes. (G) Activation level of NK-cells was studied by quantifying the activation markers CD25, CD69, and HLA-DR on NK-cells. Abbreviations: PBMCs, peripheral blood mononuclear cells, MFI, mean fluorescence index.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.